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The porphyrias are diseases that result from inherited 
or acquired abnormalities of porphyrin-heme synthesis 
in the liver and the bone marrow_ Only the hepatic 
porphyrias are known to be aggravated by exposure to 
a variety of exogenous drugs and chemicals_ Simple 
avoidance of these agents will reduce the risk of devel-
oping hepatic porphyria and may lead to clinical im-
provement in patients with active disease . Some types 
of therapy of the hepatic porphyrias are effective be-
cause of their ability to modulate the activity of <'l-ami-
nolevulinic acid synthetase, the rate-limiting enzyme for 
heme synthesis. Most of the porphyrias are associated 
with cutaneous photosensitivity, the treatment of which 
centers about either reducing the excessive production 
of porphyrins or of inhibiting the photobiological re-
sponse to these photosensitizing chemicals in the skin. 
Each of the porphyrias represents the clinical expression of 
diseases that result from abnormalities in the control of heme 
syn thesis due to aberrations in the activities of enzymes in t he 
heme pathway. Both inherited and acq uired factors play major 
roles in the development of these diseases. The clinical mani-
festation of the porphyrias appear to be du e to the toxic 
properties of porphyrins and porphyrin precursors. In normal 
individuals these biochemical intermediates are present only in 
trace amounts and are therefore vir tually innocuous. In patients 
with porphyria, the presence of excessive amounts of these 
chemicals results in pathologic changes that in tum account for 
t he recognizable clinical featw-es of these diseases. 
Rational therapy of the porphyrias requires detailed knowl-
edge of porphyrin-heme biosynthesis a nd the genetic and en-
vironmental factors that influence the activity of this pathway. 
Ideal therapy of the porphyrias would restore a berrant enzyme 
activity to normal, thereby reducing the level of the potentially 
toxic porphyrins and porphyrin precw-sors to normal. Unfor-
t unately this highly desirable therapeutic endpoint is currently 
not attainable. While it does appear possible to influence the 
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ALA: c5-aminolevulinic acid 
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UROD: uroporphyrinogen decarboxylase 
UROS: Ul'oporphyrinogen synthetase 
UROCOS: Ul'oporphyrinogen cosynthetase 
VI': vru'iegate porphyria 
activity of certain enzymes in t he heme pathway by the admin-
istration of certain drugs, no permanent alteration can be 
achieved with t he modalit ies now available. There are, however, 
a number of t reatments of the various types of porphyria. These 
range from highly effective modalities such as phlebotomy and 
chloroquine for porphyria cutanea tarda to marginally effective 
measures such as photoprotection of the skin. Fwthermore, 
avoidance of exposure to dJ'ugs and environmental chemicals 
that can alter heme pathway enzym e activity may be most 
helpful in preventing the clinical expression of porphyria. 
PORPHYRIAS AS DISORDERS OF THE REGULATION 
OF HEME SYNTHESIS 
The porphYl'in-heme pathway is ubiqui tous in biological sys-
tems. Its activi ty is carefu lly regulated such that large amounts 
of the end-prod uct heme are formed daily whereas pathway 
intermediates accu mulate and are excreted only in trace 
amounts. It is currently thought that the bone marrow and the 
liver are the major body compartments in which heme synthesis 
occurs. Bone marrow heme is needed for daily erythrocyte 
hemoglobin production and hepatic heme for a variety of heme-
proteins with relatively rapid tumover. S ince heme cannot be 
reutilized a nd is broken down into linear tetrapyrroles that 
eventuate in bilirubin production, the body must cont inuously 
synthesize heme. Heme is required as a prosthetic grou p by 
various apoproteins such as globin and apo-cytoc!11'ome P-450. 
As cellula]' heme binds to these proteins, heme levels diminish . 
This decrease in cellular heme leads to enhancement of heme 
synthesis until "normal" levels are restored. 
The rate-limit ing step for regulating hepatic heme synthesis 
is the ini t ial enzyme in the pathway, o-aminolevulinic acid 
synthetase (ALAS) (Fig 1) [1]. There are everallines of exper-
imental evidence that support the role of mitochondrial ALAS 
in controlling the rate of heme synthesis. (1) The activity of 
this enzyme is relatively low compared to that of the other 
enzymes in the pathway. (2) The half-life of ALAS is relatively 
short in mammalian liver (60-180 mins) . This is considera bly 
less than that of many mitochondrial proteins which have half-
lives of 3-5 days. (3) Activity of the enzyme can be induced or 
enhanced by cer tain types of drugs and other environmental 
chemicals as well as selected endogenous substances, particu-
larly steroid hormones and their metaboli tes. This "enzyme 
induction" permits the synthesis of larger amounts of heme 
upon demand particularly for t he production of hepatic cyto-
chl'Ome P-450, the heme-protein that is an important compo-
nent of t he microsomal enzyme system that functions in the 
metabolism of drugs and exogenous chemicals. 
The hepatocyte appears to be quite sensitive to heme levels: 
as heme falls the strLlctural gene coding for ALAS is dere-
pressed. This results in an increased rate of synthesis of this 
protein. In response to enhanced ALAS activity cellular heme 
increases. It is utilized for varioLls proteins and also functions 
as a co-repressor by binding to a putative apo-repressor protein 
which is capable of r epressing the synthesis of ALAS (Fig 2). It 
is currently though t that only a relatively small fraction of 
hepatocyte heme (which is not bound to apo-proteins) partici-
pates in this regulatory process (the so-called regulatory heme 
or free heme pool) . Certain dJ'ugs which are potent inducers of 
hepatic ALAS may trigger this effect by competing with heme 
for binding to the aporepressor; fw-thermore, drugs with phar-
macologic effects that result in reduced cellular heme levels will 
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FIG 1. o-aminolevulinic ac id synthetase (ALAS) is the rate-limiting 
enzyme for heme synthesis. 
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FIG 2. Schematic for hypothetica l m'echanisms whereby heme syn-
thesis is regulated. Heme may directly inhibi t ALAS or may function 
as a co-repressor to repress the synthesis of ALAS. 
also derepress ALAS. This can occur either by enhancing the 
destruction of existing heme (Fig 3) or by inhibiting the con-
,version of protoporphyrin to heme (Fig 4) [2,3]. 
It is importa nt to emphasize that certain of the hepatic 
porphyrias, the acute hepatic porphyrias (acute intermittent 
porphyria, variegate porphyria and heredi tary coproporphyria) , 
are each characterized by elevated hepatic ALAS activity [4). 
It is though t that deficient enzyme activi ty a~ one 01' a nother of 
the steps in the porphyrin-heme pathway leads. to a decrease in 
the regulatory or free heme pool. This in turn results in chronic 
overact.ivity (derepression) of hepatic ALAS in these patients. 
Hepatic ALAS may also be slightly increased in porphyria 
cutanea tarda perhaps due to defi cient activity of uroP0l'phYl'-
inogen decarboxylase (UROD) (inherited or acquil'ed), which 
might a lso result in diminished heme levels in the liver cell. 
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Thus in the liver the activity of the heme pathway is la.rgely 
determined by ALAS which in turn is directly r egulated b y 
heme levels within the cell. A variety of inherited or acquired 
fa cto rs may influence heme levels and thus interfere with this 
normally efficient regulatory scheme. Although most experi-
m ental evidence points to a repression-derepression mecha.nism 
for controlling hepatic ALAS activity, it is also possible that 
heme cou ld directly inhibit the enzyme. However, the levels 
required for direct enzyme inhibition (_lO- fiM ) are unlikely to 
occur in vivo. 
The regulation of heme synthesis in the bone marrow is 
poorly understood but in general ALAS does not appear to be 
rate-limiting in this tissue. There is experimental evidence to 
indicate that the activity of several enzymes in the h em e 
pathway increases slightly with accelerated demand for bemo-
globin synthesis; furthermore, bone marrow heme pathway 
enzymes normally function at or near the ir peak levels and 
. cannot be further stimulated by drugs. Recent studies indicate 
that in experimental systems, ferrochelatase may become the 
rate-limiting enzyme for heme synthesis in bone marrow [5]. 
Since the porphyrias are diseases due either to inherited 
abnormalities in heme pathway enzymes or to the effects of 
certain drugs and environmental chemicals on these enzymes, 
specific treatment should be capable of correcting these aber-
rations. Furthermore because cutaneous photosensitivity is a 
major manifestation of th e majority of the porphyrias, nonspe-
cific treatment modalities which have no demonstrable effect 
upon a bnormal porphyrin-heme synthesis may nonetheless be 
beneficial to the patient. 
The porphyrias are basically of 2 types: hepatic and eryth-
ropoietic. These are listed in Table I. Currently available treat-
ment for each of these will be discussed. 
TREATMENT OF THE PORPHYRIAS 
Acute Hepatic Porphyrias 
The acute hepatic porphyrias include acute intermittent por-
phyria, variegate porphyria and hereditary coproporphyria. 
These disorders share 2 fundam ental characteristics: (1) ele-
vated hepatic ALAS and (2) defi cient activity of specific en-
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FIG 4. Some drugs may induce hepatic ALAS by blocking h eme 
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zyme(s) in the heme pathway. As a resul t of these individual 
enzyme defects it has been proposed that regulatory heme 
levels in the hepatocytes of these patients are low, thereby 
resulting in elevated ALAS activi ty [6]. Furthermore it appears 
that th e regulation of h eme synthesis in these diseases is 
abnormal such that there is a particulal' susceptibility to drugs 
like t he barbitUl'ates which evoke increased heme synthesis by 
a ugmenting hepatic cytochrome P-450. Following ingestion of 
such drugs a cycle of increased demand for heme is coupled 
with the inabili ty of the liver cell to raise heme levels sufficiently 
high to restore the regulatory (free) heme pool to normal which 
would repress ALAS activity. 
It is of historical interest that elevated ALAS activi ty was 
t h e first enzyme abnormali ty ident ified in patients with acute 
intermittent porphyria [7,8]. S ubsequentiy, it was shown that 
t h ere was an inherited deficiency of uroporphyrinogen synthe-
tase (UROS) in patients with this disease and it is thought that 
t his results in diminished heme levels in the liver of these 
patients coupled with derepressi~n of A~AS [~]. . 
It is cUl'rentiy thought that patients With variegate porphyn a 
have increased hepatic ALAS and decreased ferrochelatase or 
protoporphyrinogen oxidase (PROTO-O) [10,11]. ~atients with 
hereditary co pro porphyria have increased hepatic ALAS and 
decreased copl'Oporphyrinogen oxidase (COPRO-O) [12]. In all 
3 of t he acute hepatic porphyrias, t he deficient enzyme activity 
is inherited in an autosomal dominant pattern . Each of these 
diseases is characterized by intermi ttent "attacks" of abdominal 
pain , autonomic dysfunction, neurop~ychiatri c syml?toms, pe-
riph eral neuropathy and paresis . Variegate p.orphyn a and he-
reditary coproporphyria are often accompamed by cutaneo us 
p hotosensitivity. It is important to emphasize that a la.l·ge 
number of drugs and steroid hormones a nd theu' metabohtes 
appear capable of triggering "attacks" of these diseases (Table 
II) . 
The treatment of the acute hepatic porphyrias includes: (1) 
avoida nce of inducer drugs, (2) carbohydrate loading, and (3) 
hematin infusions. 
Avoidance of Inducer Drugs 
Drugs which have been incriminated as capable of exacer-
bating the acute hepatic porphyrias ru'e listed in Table II: ~he 
role of t hese agents has been deduced either from the chmcal 
o bservation of patients or fro m studies in experimental systems, 
primarily the chick embryo liver ceU cul ture sys~em developed 
by Granick [13]. Avoidance of these drugs will r educe the 
number of acute attacks of porphyria in many though not all 
patients. This is s imply preventive therapy. ~ertain . p~tients 
will suffer repeated attacks of porphyria despite aVOIding ex-
posure to these agents. These may be due to horm?~al factor~, 
intercurrent infection, stru'vation, etc. Often a specIfiC etlOloglc 
factor for an acute attack cannot be identified in the individual 
patient. 
TABLE I. The porphyrias 
E rythropoietic 
H epatic 
E rythl'opoietic porphyria 
E rythropoietic protoporphYl'ia 
Acute inte rmi tten t porphyria 
Variegate porphyria 
Hereditary coproporphyria 
Porphyria eu tanea tal·da 
TABLE II. Dmgs that may induce aCllte atlaclls o(polphyria 
Barbiturates 
Methyprylone 
Meprobamate 
Amidopyrene 
Glu tethimide 
Diphenylhydantoin 
M esantoin 
Sulfo namides 
Dapsone 
Griseofulvin 
Sulfonylureas 
Estrogens 
E rgot preparations 
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Carbohydrate Loading 
It is known that the induction of hepatic ALAS in experi-
menta l a nimals by certain drugs such as aUylisopropylacetam-
ide (AlA) is lru'gely abolished by prior cal'bohydl'ate feeding of 
t he animal [14]. Furthermore, h epatic ALAS activity decreases 
in rats fed high doses of carbohydrate. These experimental 
observations provide a rationale for the use of high doses of 
carbohydrate in patients suffering from acute attacks of por-
phyria. Glucose (200-500 grams pel' day) administered orally or 
intravenously may be required. A recent study suggested that 
the use of laevulose (20%) infusions may be helpful [15]. Carefu l 
monitoring of urinary ALA and PBG excretion in selected 
patients has shown a marked decrease after carbohydrate load-
ing suggesting that hepatic ALAS activity has decreased. 
The mechanism of the "glucose-effect" is unknown. It was 
fu'st thought that the elevated carbohydrate generated large 
amounts of catabolites that coul d nonspecifically repress pro-
tein synth esis in cells. More r ecently it has been suggested that 
high carbohydrate levels in the ceU may block messenger RNA 
or may interfere in some way with the induction effects of 
steroid hormones on hepatic ALAS [16,17]. 
Hematin Infusions 
The ratio nale for t he administration of heme lies in the 
abili ty of this substance to both repress the synthesis of ALAS 
and to directly inhibi t the enzyme [18,19]. Hematin is prepared 
by crystallizing and recrystallizing hemin which is diss?lved In 
0.25% NazCO:1 [20]. Watson et al ad mini tered hematm as an 
intravenous infusion in physiologic saline (3-5 mg/ kg) once or 
twice daily. The compound is given in a bolus over 30- 60 min. 
P rompt and dramatic recovery has been reported following 
hematin infusions in 2 series of 20 a nd 11 patients [21 ,22]. ThIS 
was accompa nied by a rapid decrease in urinary ALA and PBG. 
Studies have also shown that elevated leukocyte ALAS de-
creased following hematin infusions [23]. This method of treat-
ment appears to be effective by making heme accessible to liver 
ceUs which results in repression and/ or inhibi tion of ALAS 
activity. 
It should be pointed out that hematin infusions are only 
effective in ameliorating the neuropsychiatric manifestations of 
the acute hepatic porphYl'ias. No evaluation of the efficacy of 
this modality on the photocutaneous syndl'ome of VP and HCP 
is currently available. 
POIphyria Cutanea T arda (PCT) 
Porphyria cutanea tarda is a different form of hepatic por-
phyria in which acute attacks do not occur. This disease oCC Ul.'S 
primarily in middle-aged individuals (male == female) and IS 
freq uently associated with the ingestion of drugs, such as ~lco ­
hoI and estrogens or exposure to environmental chemicals, 
particulru'ly selected halogenated hydrocarbo ns. . . . 
There now appeal' to be two major types ofPCT: (1) Inhen te.d 
and (2) acquired or sporadic. In the inherited ty~e, there IS 
defi cient activity of UROD [24]. This is t ransmitted as an 
a utosomal dominant trait a nd defici ent UROD activity has 
been detected in both the li ver a nd in red blood cells of t~ese 
patients. A second type of porphyria cutanea tarda, the acquu'ed 
or spo radic type, is indistinguishable clinically from the 1I1her-
ited type. However, deficient UROD activity may only be 
detectable in the liver of these patients [25]. Felsher, Norl'ls, 
and Shih have shown that UROD is deficient in the red blood 
cells of patients with the sporad ic type [26]. Th~ reason for 
these different findings could re late to differences 111 the meth-
odology used to meaSUl'e the enzyme. FUl'ther studies are cl.early 
needed to explain t hese apparent differences In enzymatic ac-
t ivit ies. . 
T he role of a lcohol, estrogens, hexachlorobenzene a nd o~h~r 
chlorinated hydrocarbons in the clinical expressIOn of PC r IS 
weU documented [27]. Furthermore, there is good evidence that 
PCT is usually accompa nied by iron overload in the liver. ~he 
mecha nism of the iron overload is unclear a nd the excesSIVe 
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hepatic iron may result in diminished activity of hepatic U)'O-
porphyrinogen cosynthetase (UROCOS) and UROD [28,29]. 
T he former would expla in the predominance of I-isomer por-
phyrin excretion and the latter could explain the elevated URO 
and 7-carboxyl porphyrins chamcteristic of the disease. 
Treatment of experimental animals with chlorinated hydro-
carbons such as hexachlorobenzene and tetrachlorodibenzo-p-
dioxin (TCDD) causes inhibition of hepatic UROD after a 
latent period of several weeks [30]. Iron may also play a 
permissive role in the inhibitory effect of selected halogenated 
hydrocarbons on hepatic UROD (Fig 5) [31]. In add ition recent 
studies indicate that iron-depleted mice are resistant to the 
porphyrinogenic effect of tetrachlorodibenzo-p-dioxin (TCDD) 
the most potent porphyrinogen yet identified [32]. These da ta 
aU support a fundam ental role for iron in the clinical and 
biochemical expression of PCT. Treatment measures for PCT 
include: (1) avoidance of exposure to drugs and chemicals that 
elicit the disease, (2) phlebotomy, (3) the antimala rial drugs, 
chloroquine and hydroxychloroquine, (4) metabolic alkaliniza-
tion, and (5) i.ron chelation. 
The simple avoida nce of a lcohol, estrogens and exposme to 
chlorinated hydrocal'bons will result in clinical and biochemical 
remission of PCT. However, this usually requires years. 
Phlebotomy is the treatment of choice for PCT. This modal-
ity was first shown to be effective in PCT by Ippen [33]. 
Numerous reports from throughout the world have subse-
quently verified the effi cacy of this modality in PCT [34-36]. 
The rationale, though never proven directly, rests upon certain 
critical observations: (1) hepatic siderosis frequently improves 
following phlebotomy therapy, and (2) readministration of iron 
to phlebotomy-treated patients results in clinical and biochem-
ical exacerbation of the disease [37]. 
Phlebotomy therapy can be performed in the physician's 
office. In general, it has been the experience of most investiga-
tors that the removal of 2 to 4 liters of blood is required. This 
can be done at biweekly intervals (-500 ml per phlebotomy). 
The hemoglobin is monitored until it faUs to 10-11 gm%. This 
is quite variable in the individual patient and recently it has 
been suggested that monitoringserum ferritin may be the best 
guide for assessing activity of the disease [38]. This observation 
requiTes confirmation. 
The response of PCT to phlebotomy is usually highly satis-
factory in most patients. Clinical remission does not occur for 
6-9 mos and biochemical remission may not be complete for 
12-24 mo (Fig 6). The response to therapy varies in individual 
patients. As shown in Fig 7 and 8, a single coune of phlebotomy 
may bring about a long-term remission of the disease whereas 
repeated courses of phlebotomy may be required in selected 
patients. In the latter situation careful evaluation may reveal 
that the patient has not adhered to avoidance of exposure to 
porphyrinogenic agents, particularly alcohol. Extensive clinical 
experience with phlebotomy indicates that this treatment is 
safe, well- tolerated and effective in the vast majority of patients 
with PCT. 
Treatment with the antimalarial drugs chloroquine and hy-
dJ'oxychloroquine is a satisfactory al ternative in selected pa-
ti ents with PCT. Chloroquine is an antimalarial agent that was 
ini tially thought to evoke acute attacks of porphyria, since its 
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FIG' 5. Iron is capable of enhanc ing Lhe inhibi tory effect of chlori-
nated hydl"ocru'bons on UROD. 
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administration was follow ed by "attacks" of nausea, vomiting, 
abdominal pain , and biochemical evidence of severe hepatocel-
lular necrosis [39). It has subsequently been shown that chlo-
roquin e does not exacerbate acute hepatic porphyria; rather 
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t he drug causes a selective type of hepatotoxicity in PCT [40]. 
This selective toxic effect is due to binding of the drug to the 
elevated porphyrins in the hepatocyte forming a porphyrin-
chloroquine complex [41]. This complex is highly water soluble 
and is rapidly " flushed" from the liver resulting in massive 
increases in urinary porphyrin excretion. It has also been sug-
gested that the mechanism of chloroquine action for PCT is the 
drug associated removal of iJ'on [42]. Initially it was felt that 
t h e hepatotoxic reaction was necessary for the therapeutic 
effect. It is now clear however that low-doses of the drug (125 
mg) administered intermittently (twice weekly) will bring about 
remission of the disease lasting months to years without hepa-
totoxicity [43,44]. 
The onset of remission of PCT induced by the antimalal'ial 
drugs is generally similar to that evoked by phlebotomy, How-
ever, there is a dose-response relationship in that higher initial 
doses of these drugs do result in a more rapid onset of clinical 
and biochemical remission , The length of remission may be 
shorter than that associated with phlebotomy. Malkinson and 
Levitt treated 6 patients with PCT using hydroxychloroquine 
[45]. Initial doses were 100 mg 3 times weekly for 1 mo, then 
200 mg 3 times weekly for 1 mo and then 200 mg daily, 
Thereafter the daily dose was increased to 300 mg 01' 400 mg 
depending upon the clinical and biochemical response. Treat-
ment periods ranged from 5 to 13 mo and both clinical and 
biochemical remission occurred. Four of 6 patients in remission 
followed for 9 to 24 mo had relapses. Three of the 4 were again 
retreated with hydroxychloroquine and again improved or went 
into remission, It was concluded that prolonged remissions may 
not OCCUI' in PCT patients treated with the antimalarial drugs, 
It is important to emphasize, however, that these patients were 
not instructed to discontinue alcohol ingestion, 
It has also been suggested that the combination of phlebo-
tomy and chloroquine is effective in PCT and that phlebotomy 
prior to chloroquine administration reduces the risk of hepa-
totoxicity of the latter [46]. 
TREATMENT OF PORPHYRIAS III 
Metabolic AlIwlinization 
This method of t reating PCT is based upon the difference in 
pK of coproporphyrin and Ul'oporphyrin [46]. It has not been 
uniformly successful and is not in current use, 
Iron Chelation 
While theoretically desirable, the use of iron chela tors has 
not been satisfactory [47). The requirement for repeated painful 
injections of desferroxamine has greatly limited its use partic-
ularly since other highly effective modalities such as phlebo-
tomy and the antinlalarial drugs are available, It is entirely 
possible t hat newly developed less toxic iron chelators could 
offer an effective approach to the treatment of PCT. 
Elylhl'Opoietic Porphyria (EP)-(Giinther's Disease) 
This is a rare type of porphyria charactel'ized by mutilating 
cutaneous photosensi t ivi ty and abnormal porphyrin-heme syn-
thesis in the bone marrow. This disease usually is ma nifest 
early in life as severe photosensit ivity with red-stained fluores-
cent teeth (erytru'odontia) and reddish discoloration of the 
urine. The photosensitivi ty is associated with hypertrichosis 
combined with scarring. Repeated episodes of cutaneous pho-
tosensitivity result in sclero t ic changes in light-exposed skin 
that may resemble scleroderma. 
In addition to photosensitivity, many patients suffer from 
hemolytic anemia. Circulating "erythroblasts" are rich in por-
phyrins and therefore, highly fluorescent RBC's are detectable. 
The life span of the erytlU'ocyte is frequently shortened and 
splenomegaly often develops. Whether the hemolytic a nemia is 
due to "photo-hemolysis" of circula t ing porphyrin-laden eryth-
rocytes remains controversial [48]. 
The enzymatic abnormality in EP is unclear. Romeo and 
Levin have shown that UROCOS activity is decreased to 1/ 3 to 
1/ 10 of the normal level in pa ti ents with EP [49]. Others have 
shown that there is a general increase in the activi ty of several 
heme pathway enzym es in EP [50]. This has led to the hypoth-
esis that the primary control of heme biosynthesis in EP is at 
the level of ALAS with a secondary control point at the level of 
UROCOS. Further studies are needed to clarify the specific 
enzyme defect(s) in EP. 
The treatment of EP remains unsatisfactory. Splenectomy in 
patients with hemolytic anemia a nd splenomegaly is said to be 
helpful in diminishing hemolysis and thereby perhaps reducing 
the circulating porphyrin load [51]. Chloroquine ad ministration 
(125 mg twice weekly) has been advocated as a method to 
improve erytru'ocyte fragility and thereby diminish hemolysis 
[52]. Shielding in light-opaque celluloid is said to reduce cuta-
neous photosensitivity [53]. Hematin infusions have been uti-
lized with paJtial r eduction of porphyrin production in a single 
patient [54]. No long-term studi es have been performed to 
evaluate the usefuln ess of this modality. Metabolic' a lkaliniza-
tion was attempted in 2 patients without success [55]. 
Elythropoietic Protoporphyria (EPP) 
This is one of the more common types of porphyria and is 
characterized by a milder form of cutaneous photosensitivi ty 
than that seen in EP. The disease usually begins in early 
childhood and the primary complain t often is that of stinging, 
burning and swelling of the skin during 01' shortly after sun 
exposure [56]. Repeated episodes resu lt in wax-like lineal' SCal'S 
on the bridge of the nose a nd on the bony prominences of the 
hands. Histopathologic examinat ion of the skin from these 
areas shows massive amounts of PAS-positive material in and 
around the vessels of the upper dermis. In most patients cuta-
neous photosensitivity is the sole clinical manifestation of the 
disease [56]. 
Cholelithiasis occurs more frequently than in the normal 
population and the stones are rich in PROTO [57]. A minority 
of patients have developed liver disease which may progress 
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inexorably to terminal hepatic failme [58]. The mechanism of 
this fatal complication is unclear. 
Defective activity of ferrochelatase has been identified in 
bone marrow, liver, cul tured skin fibroblasts, nucleated red cells 
and mitogen stimulated lymphocytes of patients with EPP 
[59]. 
It is important to point out that elevated erytlu'ocyte PROTO 
is not unique to EPP. In both lead poisoning and in severe iron-
deficiency anemia, elevated levels of PROTO also occur and yet 
no cutaneous photosensitivity develops. This has been ex-
plained by chemical differences in the PROTO in EPP as 
compared to that in lead poisoning and iron-defi ciency anemia 
[60]. In the latter 2 disorders, the excessive RBC PROTO is 
chelated with zinc and is apparently unable to diffuse out of 
the red cell. In EPP, the excessive PROTO is unchelated or 
free a nd is capable of diffusing from the red cell into the plasma 
and ul timately into cutaneous t issue where it can absorb solar 
energy a nd resul t in cuta neous photosensitivity. 
T he treatment of EPP centers about management of the 
cutaneous photosensitivity and the hepatic failme that may 
occur in a small number of patients with this disease. The single 
effective treatment currently available for the cutaneous pho-
tosensit ivity in EPP is beta-carotene. 
Orally administered beta-carotene has improved cutaneous 
photosensitivity in 84% of 133 patients [61]. T his was assessed 
by determining the a bility of patients to tolerate sun exposure 
before and after treatment with beta-carotene. The drug is 
available in 30 mg capsules (Solatene) which are usually ad-
ministered in doses of 60 to 180 mg/day. Toxic reactions have 
been limited to transient loose stoo ls a nd to carotenodermia, a 
yellow-orange discoloration of the skin due to cutaneous depo-
sition of the drug. 
The mechanism of action of beta-carotene in EPP is contro-
versial. Photo-excited PROTO is in the triplet state and may 
destroy cellular components directly or react with oxygen to 
form singlet oxygen wruch can oxidize lipid-rich membranes in 
t he cell. This in turn could result in t he release of lysosomal 
hydrolases that would produce. tissue damage. Beta-carotene is 
known to quench free radicals and singlet oxygen [62]. Whether 
these effects have a ny relationship to the clinical improvement 
of photosensitivity seen in most patients with EPP is unknown. 
It is of interest t hat beta-carotene apparently does not r educe 
the erythrocyte PROTO levels in EPP. In fact it has been 
shown that RBC PROTO actually increases slightly in patients 
receiving beta-carotene [63]. The drug is known to protect 
against erythrocyte lysis by PROTO in vitro [64]. It is also 
possible that leakage of PROTO may be prevented by beta-
carotene. This migh t result in less diffusion of RBC PROTO 
into the ski.n, thereby reducing the severity of th e cutaneous 
photosensit ivity. It should be pointed out that one clinical study 
concluded that beta-cal'otene was ineffective in preventing pho-
tosensit ivi ty in EPP [65). . 
At least 15 cases of terminal hepatic failme in patients with 
EPP have been reported [59). The liver disease is characterized 
by direct hyperbilirubinemia and mild-to-moderate increases in 
transaminase and alkaline phosphatase. Liver biopsy demon-
strates ci.rrhosis with massive deposits of dark brown pigment 
which may be precipitated PROTO. 
The treatment of hepatic disease in EPP is directed at 
, depleting the excessive PROTO stores in t he liver by interrupt-
ing the enterohepatic circulation of the porphyrin. Cholestyra-
mine, a nonabsorbed binder of anions, has been used for this 
pmpose. One patient was treated with cholestyramine (12 gm/ 
day in divided doses) and t he antioxidant vij;amin E (100 units 
daily) [59]. Over a period of 11 mos plasm a PROTO decreased 
and liver function tests returned to normal. Liver biopsy also 
showed a reduction in cellular necrosis and inflammalion 
though cirrhosis persisted. Pigment deposition also diminished. 
This treatment should be attempted in addit ional patients. 
T he au thor acknowledges the help of Ms. Betty Hickle and Ms. 
Karen Motuza who typed the manuscript. 
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